logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
W

Wenfeng Fang

department of medical oncology
H指数:47
被引数:9,805

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integration of a severe immune-related adverse events predictive model with efficacy biomarkers enables precise stratification in NSCLC immunotherapy: insights from the phase 3 ORIENT-11 study

将严重免疫相关不良事件预测模型与疗效生物标志物相结合，可实现NSCLC免疫治疗中的精确分层：来自III期ORIENT-11研究的见解

Cancer Immunology Immunotherapy
IF5.1
2026-08-260
OA
Yue Peng; Ling Wen; Jiayi Shen; Jianhua Zhan; Huaqiang Zhou; Jiaqing Liu; Gang Chen; Yaxiong Zhang; Shen Zhao; Yuanyuan Zhao; Yan Huang; Wenfeng Fang; Yunpeng Yang; Haishuang Sun; Li Zhang; Dongchen Sun
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

伊沃奈司单抗联合化疗与安慰剂联合化疗在EGFR突变型晚期非小细胞肺癌患者中的疗效比较（患者既往接受EGFR酪氨酸激酶抑制剂治疗后疾病进展）（HARMONi研究）：一项多中心、随机、双盲、Ⅲ期临床试验

Lancet Oncology
IF35.9
2026-08-240
PRE
Xiuning Le; Antonio Passaro; Yuanyuan Zhao; Yan Huang; Janessa Laskin; Delvys Rodriguez-Abreu; Antonio Calles; Lyudmila Bazhenova; Giuseppe Lo Russo; Natasha B Leighl; Federico Cappuzzo; Nicolas Girard; Sanjay Popat; Wenfeng Fang; Yongzhong Luo; Wenting Li; Zhiyong He; Hui Zhao; Mingjun Li; Qibin Song
Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies

基于真实世界研究的帕博利珠单抗与化疗在中国晚期非小细胞肺癌中的成本效益分析

Journal of Cancer Research and Clinical Oncology
IF2.8
2025-10-280
OA
Ning Wan; Chen Yang; Bing Wang; Ya Guo; ZiJian He; YaJuan Lv; LiQing Lu; Ning Yang; WeiBin Xiao; YongBang Chen; Jin Yuan; DanDan Yang; Tao Liu; WenFeng Fang; ZhuoJia Chen; WeiTing Liang
First case report of immune checkpoint inhibitor-related pneumonitis triggered by bispecific antibody (anti-PD-L1 and anti-CTLA-4) in a patient with non-small cell lung cancer: case report

首例免疫检查点抑制剂相关肺炎病例报告：1例非小细胞肺癌患者接受双特异性抗体（anti-PD-L1和anti-CTLA-4）治疗后诱发肺炎：病例报告

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-09-301
PRE
Sun, Haishuang; Liu, Yu; Chen, Zihong; Fang, Wenfeng; Zhang, Li; Zhang, Yaxiong
Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis

可切除非小细胞肺癌围手术期、辅助及新辅助化免疫治疗的有效性与安全性：基于临床分期和PD-L1表达的系统评价和网络Meta分析

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-09-300
PRE
Wang, Yuanyuan; Zhang, Lin; Zhao, Xinyuan; Sun, Dongchen; Zhou, Huaqiang; Zhang, Yaxiong; Chen, Gang; Liu, Tingling; Liu, Jiaqing; Zhao, Yuanyuan; Huang, Yan; Fang, Wenfeng; Zhang, Li; Yang, Yunpeng
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial

一线sacituzumab tirumotecan联合tagitanlimab治疗晚期非小细胞肺癌：一项Ⅱ期临床试验

Nature Medicine
IF50
2025-08-190
PRE
Shaodong Hong; Qiming Wang; Ying Cheng; Yongzhong Luo; Xiujuan Qu; Haibo Zhu; Zhenyu Ding; Xingya Li; Lin Wu; Yan Wang; Sheng Hu; Enwen Wang; Anwen Liu; Yuping Sun; Yun Fan; Feng Ye; Kaihua Lu; Jian Fang; Yuping Shen; Xiaoping Jin; Junyou Ge; Li Zhang; Wenfeng Fang
Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors

ADG106（一种4-1BB/CD137激动剂）与托利法利木单抗联合治疗晚期实体瘤的Ⅰb/Ⅱ期研究

ISCIENCE
IF4.1
2025-05-010
OAAI
Lin, Shaoyan; Ma, Yuxiang; Wang, Yongsheng; Yang, Yunpeng; Xue, Jinhui; Huang, Yan; Zhao, Yuanyuan; Fang, Wenfeng; Hong, Shaodong; Zhang, Yang; Liu, Qianwen; Liu, Guizhong; She, Xiaohong; Zha, Jiping; Zheng, Songmao; Li, Yan; Luo, Peter
Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial

在线自适应磁共振引导分割立体定向放射治疗非小细胞肺癌脑转移的疗效与安全性（GASTO-1075）：一项单臂、Ⅱ期临床试验

ECLINICALMEDICINE
IF10
2025-04-010
OAAI
Zheng, Shiyang; Ding, Shouliang; Liu, Biaoshui; Xiong, Yixin; Zhou, Rui; Zhang, Pengxin; Liu, Fangjie; Liu, Yimei; Chen, Meining; Situ, Yu; Wang, Mengru; Huang, Xiaoyan; Yin, Shaohan; Fang, Wenfeng; Mou, Yonggao; Qiu, Bo; Wang, Daquan; Liu, Hui
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial

抗LAG-3抗体LBL-007联合抗PD-1抗体toripalimab治疗晚期鼻咽癌及其他实体瘤：一项开放标签、多中心、 Ib/II期临床试验

JOURNAL OF HEMATOLOGY & ONCOLOGY
IF40.4
2025-02-073
OA
Chen, Gang; Sun, Dong-Chen; Ba, Yi; Zhang, Ya-Xiong; Zhou, Ting; Zhao, Yuan-Yuan; Zhao, Hong-Yun; Fang, Wen-Feng; Huang, Yan; Wang, Zhen; Deng, Chao; Hu, De-Sheng; Wang, Wei; Lin, Jin-Guan; Li, Gui-Ling; Luo, Su-Xia; Fu, Zhi-Chao; Zhu, Hai-Sheng; Wang, Hui-Li; Cai, Sheng-Li; Kang, Xiao-Qiang; Zhang, Li; Yang, Yun-Peng
Surufatinib plus toripalimab combined with pemetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial

苏鲁法替尼 plus 托瑞帕利姆单抗 combined with 帕emetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Fang, W. F.; Yang, Y.; Huang, Y.; Zhao, Y.; Zhang, Y.; Zhou, T.; Chen, G.; Zhao, S.; Ma, Y.; Hong, S.; Zhao, H.; Zhang, L.
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China

人类表皮生长因子受体2抗体-药物偶联物诱导的间质性肺疾病/肺炎跨学科管理的临床最佳实践: 中国专家共识

CANCER
IF5.1
2024-08-021
PRE
Xu, Chunwei; Chen, Zhanhong; Xia, Yuanli; Shi, Yanxia; Fu, Peifen; Chen, Yiding; Wang, Xian; Zhang, Lili; Li, Hengyu; Chen, Wenyan; Fu, Jianfei; Huang, Liming; Shu, Jingde; Wang, Ouchen; Wu, Weizhu; Xie, Bojian; Wang, Ting; Zhang, Weiping; Shen, Shurong; Li, Qun; Luo, Ting; Zhang, Bin; Xie, Yanru; Wang, Hongxia; Wang, Qian; Wang, Wenxian; Li, Ziming; Song, Zhengbo; Fang, Wenfeng; Zhong, Wenzhao; Zhang, Yongchang; Zhan, Ping; Liu, Hongbing; Lv, Tangfeng; Miao, Liyun; Min, Lingfeng; Wang, Feng; Meng, Rui; Zhu, Youcai; Wang, Lin; Wan, Bing; Wang, Dong; Hao, Yue; Zhou, Jianya; Huang, Long; Zhang, Zhang; Lv, Donglai; Fang, Meiyu; Lu, Yuanzhi; Si, Lu; Song, Yong; Wang, Xiaojia

研究方向

暂未获取到该数据
Y
Yunpeng Yang
H 指数:47论文数:382被引数:9,344
Y
Yan Huang
H 指数:50论文数:410被引数:9,807
H
Hongyun Zhao
H 指数:52论文数:706被引数:1.0万
洪
洪少东
H 指数:39论文数:241被引数:7,041
Y
Yuanyuan Zhao
H 指数:43论文数:266被引数:5,968
马
马宇翔
H 指数:41论文数:257被引数:6,044
Y
Yaxiong Zhang
H 指数:31论文数:130被引数:4,059
L
Li Zhang
H 指数:44论文数:225被引数:6,849
L
Li Zhang
H 指数:52论文数:455被引数:1.4万
T
Ting Zhou
H 指数:31论文数:192被引数:3,390